Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15394807 | 0.90 | MAOB (0.58) | MAOBMRGPRX4MAOASMN1; SMN2MBTPS1 | |
| SCHEMBL12420571 | 0.80 | MAOB (0.59) | MAOBMAOAMBTPS1 | |
| Hydrochloric Acid SCHEMBL2195214 | 0.79 | MAOB (0.58) | MAOBMAOAMBTPS1 | |
| SCHEMBL9542255 | 0.78 | LMNA (0.53) | MAOBMRGPRX4SMN1; SMN2CYP2C19SMPD1 | |
| SCHEMBL3455822 | 0.75 | MEN1 (0.55) | MAOBSMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL8738173 | 0.74 | SLC6A4 (0.59) | SMN1; SMN2NPC1ALDH1A1RAB9A | |
| SCHEMBL14967427 | 0.73 | MRGPRX4 (0.76) | MAOBMRGPRX4MAOASMN1; SMN2NPC1 | |
| SCHEMBL3456937 | 0.73 | MAOB (0.57) | MAOBMAOAALDH1A1SMPD1 | |
| SCHEMBL30938340 | 0.73 | HTR2C (0.49) | ALDH1A1 | |
| SCHEMBL14966572 | 0.72 | MAOB (0.63) | MAOBMRGPRX4MAOASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310379-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | TET1, TET3, EHMT2 | MAOB 288/4885MRGPRX4 3922/4885MAOA 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.